Onflict of interest.Oxygen 2021,
pathogensReviewVancomycin Use in Children and Neonates across
Onflict of interest.Oxygen 2021,
pathogensReviewVancomycin Use in Youngsters and Neonates across 3 Decades: A Bibliometric Evaluation of the Top-Cited ArticlesChiara Minotti , Elisa Barbieri , Carlo Giaquinto and Daniele DonDivision of Pediatric Infectious Diseases, Department of Women’s and Children’s Health, University of GYKI 52466 Autophagy Padova, 35100 Padova, Italy; [email protected] (E.B.); [email protected] (C.G.); [email protected] (D.D.) Correspondence: [email protected]: Vancomycin is frequently prescribed in pediatrics, in particular in intensive care unit settings, to treat Gram-positive bacterial infections. This perform aims to gather the top-cited articles of pediatric and infectious illnesses regions to collect the existing evidence and gaps of knowledge around the use of vancomycin in these populations. Essentially the most relevant journals reported inside the “pediatrics” and “infectious diseases” categories on the 2019 edition of Journal Citation Reports were browsed. Articles with more than 30 citations and published during the last three decades were collected. A bibliometric analysis was performed and 115 articles were retrieved. They had been published in 21 journals, with a median impact issue of four.6 (IQR two.9.four). Sixty-eight of them (59.1 ) belonged to “infectious diseases” journals. The most relevant subject was “bloodstream/complicated/invasive infections”, followed by “antibiotic resistance/MRSA treatment”. As for population distribution, 27 articles were on young children only and 27 on neonates, the majority of which had been from intensive care unit (ICU) settings. The current literature mainly bargains with vancomycin as a therapy for severe infections and antibiotic resistance, specially in neonatal ICU settings. Lately, attention to new GNE-371 Cell Cycle/DNA Damage dosing approaches inside the neonatal and pediatric population has turn into a sensible subject.Citation: Minotti, C.; Barbieri, E.; Giaquinto, C.; Don D. Vancomycin Use in Young children and Neonates across Three Decades: A Bibliometric Evaluation on the Top-Cited Articles. Pathogens 2021, ten, 1343. https:// doi.org/10.3390/pathogens10101343 Academic Editor: Steven L. Zeichner Received: 23 July 2021 Accepted: 29 September 2021 Published: 18 OctoberKeywords: vancomycin; bibliometric analysis; top-cited articles; pediatric infectious ailments; kids; neonates1. Introduction Vancomycin is amongst the most frequently prescribed glycopeptides, specifically in young children and newborns in intensive care unit (ICU) settings for the remedy of Grampositive bacterial infections by coagulase-negative Staphylococci (CoNS), Enterococci spp, methicillin-resistant Staphylococcus aureus (MRSA), and C. difficile. It inhibits cell wall synthesis by binding towards the D-Ala-D-Ala terminal from the peptide chain and features a volume of distribution of 0.4 L/kg [1]. There’s substantial variability in protein binding, which is believed to be up to 50 [2]. Its bactericidal activity is connected to the location under the curve (AUC) and minimal inhibitory concentration (MIC) ratio (AUC/MIC ratio), which, as stated within the literature, has to be higher than 400 to assure standard efficacy [1]. Serum levels monitoring is encouraged, having a target trough concentration objective of 150 /mL for severe infections. Depending on these pharmacodynamics data, continuous infusion of vancomycin has been proposed for severe infections, guaranteeing greater steady-state concentrations. On the other hand, there is small consensus on selecting the optimal dosing regimen and administration schedule (in.
Heme Oxygenase heme-oxygenase.com
Just another WordPress site
